| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.4 | 0.6 | 1.5 |
| Total income | 0.4 | 0.6 | 1.5 |
| Profit before exceptional items & tax | 0.2 | -0.4 | 1.3 |
| Profit before tax | 0.2 | -0.4 | 1.3 |
| Net profit | 0.2 | -0.4 | 1.3 |
| Operating margin | 50.0% | -66.7% | 86.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -84.60% |
|---|---|
| Revenue, year on year | -73.30% |
BSE results filing, NSE: SUNTECHNO. Figures extracted from the filing.
Biogen Pharmachem Industries Ltd: key numbers
- Share price
- ₹0.28
- Market cap
- ₹29.49 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.86 Cr
- P/E (TTM)
- -177.2×Sector 21.8×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biogen Pharmachem Industries Ltd
All →Biogen Pharmachem Industries Annual Report
Biogen Pharmachem Industries Limited submitted its 31st Annual Report for the financial year 2025-26. The Annual General Meeting is scheduled for September 29, 2026.
Biogen Pharmachem Industries Annual General Meeting
Biogen Pharmachem Industries Ltd has issued a notice for its 31st Annual General Meeting scheduled for September 29, 2026. The meeting will be held via video conferencing.
Biogen Pharmachem Industries Other Announcement
Biogen Pharmachem Industries Limited has reported no unutilised funds from any prior capital raises, including public issues, rights issues, or preferential allotments, as of June 2026.
Biogen Pharmachem Industries Board Meeting Date
Biogen Pharmachem Industries Limited scheduled a Board meeting for August 5, 2026. The meeting will consider and approve financial results for the quarter ended June 30, 2026.
Biogen Pharmachem Industries Other Announcement
Biogen Pharmachem Industries submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The company confirmed compliance with all applicable SEBI regulations and secretarial standards.
Biogen Pharmachem Industries Other Announcement
Interface Financial Services Limited sold a 4.47% stake in Biogen Pharmachem Industries through the open market. This reduces their total equity holding to 4.84%.